Users Coming Off Anti-Obesity Medications Gain Back Weight at a Quadrupled Rate Than Dieters

A recent study reveals that individuals who discontinue new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional diet and exercise regimens.

Published data in a prominent medical journal shows that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.

"Individuals buying such medications should be aware of the risk of rapid weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.

Such speed of regain suggests a return to pre-treatment mass within about 18 months.

Analyzing Therapies

The research, which examined dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.

Scientists note that individuals who lose weight through lifestyle changes alone generally see a less rapid creep back—approximately 0.1 kg a month—post-intervention.

Explaining the Fast Rebound

Nutrition scientists suggest the mode of action of the drugs accounts for the accelerated weight return.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this hormone supplement means appetite is uncontrolled, making excessive eating far more likely."

An Ongoing Issue?

The NHS suggest the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

A number of clinicians contend that, due to the likelihood of weight regain, the therapy should be considered life-long.

This opinion is reinforced by drug manufacturers, who say that the results "underscore the chronic nature of obesity," akin to managing conditions like hypertension.

User Experiences

Users who have discontinued the medication explain a sudden resurgence of hunger.

"It was like a switch flipping and I was suddenly extremely hungry," said an individual.

This challenge is worsened if users have not developed lasting lifestyle or habit changes during therapy.

Widespread Adoption

Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.

• Adoption is more common among females compared to men.
• The 40s and 50s demographic shows the greatest usage rates.
• Many obtain the drugs through private healthcare rather than the NHS.

Finally, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and maintained weight loss hinges on combined behavioural support.